


Attorney Docket No.: P26318



1AP16 Rec'd PCT/PTO 11 MAY 2009

Application No.: 10/516,292

PC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Susumu MUTO et al.

Confirmation No.: 5595

Group Art Unit: 1614

Appl. No. : 10/516,292

(U.S. National Stage of PCT/JP03/07121)

I.A. Filed : June 5, 2003

Examiner: Charlesworth E. RAE

For : THERAPEUTIC AGENT FOR CANCER

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98 and supplemental to the Information Disclosure Statements filed February 24, 2006, March 7, 2006, and July 28, 2006, Applicants hereby direct the Examiner's attention to In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and further to the Information Disclosure Statements filed February 24, 2006, March 7, 2006, and July 28, 2006; and January 6, 2009, Applicants hereby direct the Examiner's attention to the following documents cited in the Partial European Search Report for European Application EP 07 01 5427, of which the above-referenced application is a counterpart application:

- (1) US 6 117 859, Applicants note that this document was listed in the Information Disclosure Statement of February 24, 2006;
- (2) EP 0 221 221 A, Applicants note that this document was listed in the Information Disclosure Statement of February 24, 2006;
- (3) JP 37 000 225 B, January 23, 1962, accompanied by an English language

abstract thereof;

05/12/2009 CNGUYEN2 00000007 10516292

01 FC:1806

180.00 OP

- (4) WO 99/55663 A1, Applicants note that this document was listed in the Information Disclosure Statement of February 24, 2006;
- (5) EP 0 221 346 A1, Applicants note that this document was listed in the Information Disclosure Statement of February 24, 2006;
- (6) WO 00/35442 A1, Applicants note that this document was listed in the Information Disclosure Statement of February 24, 2006;
- (7) EP 0 081 782 A1, June 22, 1983
- (8) WO 99/65449 A1, Applicants note that this document was listed in the Information Disclosure Statement of February 24, 2006;
- (9) MADAN et al., Molecular Pharmacology, 2000, Vol. 58, No. 3., pp. 526-534, Applicants note that this document was listed in the Information Disclosure Statement of February 24, 2006; and
- (10) JP 62 099329 A1, Applicants note that this document was listed in the Information Disclosure Statement of February 24, 2006.

Furthermore, Applicants direct the Examiner's attention to the following document:

- (11) EP 1 113 000 A1, April 7, 2001; Applicants note that this document was cited in the Supplementary European Search Report for European Application EP 03 73 0837, Applicants note that all other documents cited in the Supplementary European Search Report for European Application EP 03 73 0837 were made of record in the Information Disclosure Statement filed January 6, 2009.


Copies of the above-listed documents (3), (7) and (11), the Partial European Search Report for European Application EP 07 01 5427 and the Supplementary European Search Report for European Application EP 03 73 0837 are enclosed together with a completed copy of the Form PTO-1449 listing these documents. Accordingly, the

Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the Form PTO-1449 with the next communication.

Applicants note that a non-final Office Action has issued in the instant application on October 6, 2008. Therefore, to ensure consideration of the enclosed materials pursuant to 37 C.F.R. § 1.97(c), Applicants submit herewith the requisite fee under 37 C.F.R. 1.17(p). If for any reason the requisite fee is not enclosed herewith or any additional fee is required, the undersigned authorizes the Office to charge Deposit account 19-0089 any fee necessary to ensure the consideration of the submitted materials.

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted,
Susumu MUTO et al.


Bruce H. Bernstein
Reg. No. 29,027

May 11, 2009
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Stephen M. Roylance
Reg. No. 31,296